reast magnetic resonance imaging (MRI) is ext t tremely sensitive in the detection of carcinoma, with a sensitivity ranging from 97% to 100%. 1 The specificity is somewhat lower, ranging from 50% to 80% as reported previously. 2, 3 The wide range of specificity may be due to the fact that investigators at different institutions use a variety of MR imaging techt t niques for acquiring and processing images and possibly use different criteria for interpretation. This may also be partly due to differing levels of experience with MR mammography. Given these limitations when interprett t ing a study, it is important for a radiologist to detert t mine which lesions are suspicious of malignancy and need to be biopsied. A standardized terminology has been developed to facilitate the interpretation and comt t 
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reast magnetic resonance imaging (MRI) is ext t tremely sensitive in the detection of carcinoma, with a sensitivity ranging from 97% to 100%. 1 The specificity is somewhat lower, ranging from 50% to 80% as reported previously. 2, 3 The wide range of specificity may be due to the fact that investigators at different institutions use a variety of MR imaging techt t niques for acquiring and processing images and possibly use different criteria for interpretation. This may also be partly due to differing levels of experience with MR mammography. Given these limitations when interprett t ing a study, it is important for a radiologist to detert t mine which lesions are suspicious of malignancy and need to be biopsied. A standardized terminology has been developed to facilitate the interpretation and comt t Reporting and Data System (BItRADS), 4 in the form of a lexicon, that is widely used in the United States, was implemented in our hospital a few years back. It is now the standard for reporting conventional xtray mammot t grams and uses descriptors to attach a level of suspicion to a lesion and its need for a biopsy. The same lexicon can be used for reporting MRI breast. 4 The use of morphologic criteria has been shown to improve specificity when used to describe breast findings on MRI. 5, 6 For example, smooth or lobulated margins on MRI show a 97% to 100% predictive value for benignity, whereas the presence of rim enhancement shows a 79% to 92% predictive value for malignancy. 5 Despite these encouraging results, the value of morphologic criteria to describe MRItdetected breast lesions has been limited by the lack of a definitive classification scheme. In 1999, Fischer et al 1 developed a scoring system to predict the likelihood of a lesion on MRI as being benign or malignant. After the magnetic resonance mammograt t phy (MRM) BItRADS classification system (that mirt t rors the mammographic BItRADS categories) was det t scribed in 2003 by the American College of Radiologists (ACR), 4 we found that the Fischer scoring system made identifying the BItRADS category much easier for inext t perienced radiologists. Our study was performed to ast t sess whether this scoring system would help beginners to accurately diagnose breast lesions on MR imaging and to assess the correlation between the MRM BItRADS grade and the final diagnosis.
PATIENTS AND METHODS
In this single center prospective study conducted in a breast unit of a general hospital, 41 consecutive cases with identified breast lesions on mammography presentt t ing during the period May 2005 to September 2006 underwent an initial dynamic MR mammography of the breast with followtup imaging studies as required up to 2 years. The study was conducted using a 1.5T magt t net (GE Excite, South Carolina, USA) and the patients constituted part of our initial experience with MR mamt t mography. 7 The patients included in our study were referred to our MR imaging suite with breast lesions for the followt t ing reasons:
1. Equivocal findings on mammography (n=18), 2. Suspicion of local relapse in treated breast cancer patients (n=6), 3. Search for a primary breast cancer in patients with metastatic axillary lymph nodes with suspicious lesion on mammography (n=5), 4. Local staging of breast cancer (suspicion of multiple lesions at standard imaging, dense breasts) (n=5), 5. Differentiation between inflammatory benign let t sions vs. inflammatory carcinoma (n=4), 6. MRI screening in hightrisk patients with lesion suspicious for cancer on mammography (n=3). We analyzed the morphologic characteristics, ent t hancement pattern and kinetic features of the lesions and assigned an appropriate final assessment BItRADS category ( Table 1) . The aim of the study was to assess whether the descriptive terminology and final assessment categories of the BItRADS lexicon using the Fischer scoring system 1 corresponded to the final diagnosis of the lesions as obtained from histopathological confirmation or followtup.
Patient preparation and positioning
A 20tgauge intravenous line was inserted at the dorsum of the hand before positioning the patient on the table to ensure lack of movement between scans. The MRI breast was performed with the patient lying in a prone position on a platform placed in the MR imager that allows the breasts to be in a dependent position. A dedicated 4t channel breast coil was used. MRI was performed during days 6t16 of the menstrual cycle or after stopping hort t mone replacement therapy for 4t6 weeks to avoid false positive enhancing lesions during the peak hormonal level of the cycle. If the MRI was requested for suspected recurrence of malignancy, the MRI study was performed 6t8 weeks post surgery and at least 9 months (preferably 12 months) post radiotherapy. with effective slice thickness of 2.0 mm) were then obtained with a scan time not exceedt t ing 60 sec per scan. Seven acquisitions were obtained sit t multaneously of both breasts. The first acquisition was obtained before contrast was injected and was used as a mask and the other 6 acquisitions were obtained folt t lowing contrast injection. The posttcontrast acquisitions were finished within 6 minutes. The contrast used was 0.1 mmol/kg of gadoliniumtDTPA intravenously, usualt t ly injected as a bolus using an automatic injector at a rate of 2mL/sec, followed by a saline flush. The last sequence obtained post contrast was a high T1W spatial resolut t tion sequence; axial 3D SPGR volume fat saturated T1 (slice thickness 4 mm, 44 loc per slab, FOV 30, matrix 416×256, NEX 1, flip angle 35, bandwidth 41.67) which was done at almost 7t8 minutes post contrast.
Image interpretation
The morphology of the lesion was studied on the 3D volume T1W images, the fat saturated post contrast 3D volume T1W images and the fat saturated T2W images and images obtained posttprocessing (maximum intent t sity projection and maximum slope of signal increase). The form, margin and the enhancement pattern of the lesions were identified and scored points as in Table 1 .
Evaluation of enhancement kinetics following contrast agent administration was done on the posttprocessed dyt t namic images using the software function tool 2.6.4b3 of GE to measure the signal enhancement ratio within the lesions and identify the enhancement curves. Since accut t rate placement of a region of interest over the areas of most rapid and intense enhancement is critical we used color mapping of the lesions as a guide. We followed the quantitative method described by Fischer et al 1 to study the enhancement curves.
Evaluating the enhancement curves based on Fischer's group
The evaluation criterion was the peak percentage of signal intensity increase within the first 3 minutes after contrast material administration relative to the precont t trast signal intensity (initial signal intensity increase). The initial signal intensity increase within 3 minutes was given a value of less than 50%, 50% to 100% and more than 100%. Furthermore, we evaluated the behavt t ior of the signal intensity curve from the 3rd to the 7th minute. A signal intensity increase of more than 10% within this interval relative to the peak enhancement in the first 3 minutes was defined as "continued signal int t tensity increase" (giving a type I curve). A signal intent t sity similar to the peak signal intensity was considered as a plateau (giving a type II curve), and a decrease of more than 10% was defined as a washout (giving a type III curve).
The Fischer scoring system
In this scoring system, five dynamic contrasttenhanced MR features are evaluated. These comprised three mort t phological (shape, margins, enhancement kinetic) and two functional features (initial peak of signal intensity increase and behaviour of signal intensity curve) cont t stituting a multifactorial protocol in which each critet t rion receives a point value. Each parameter is assigned points ranging from 0 to 1 or 0 to 2, with higher points for those that are more likely to be associated with mat t lignancy. The sum of all the points defines the degree of suspicion of malignancy, with a score 0 representing the lowest and 8 the highest degree of suspicion ( Table  1) . The points are then assigned a BItRAD category); 0 and 1 point correspond to category I (negative, no abnormal enhancement, enhancing masses or archit t tectural distortion, 2 points corresponds to category II (benign findings, for routine follow up), 3 points cort t respond to category III (probably benign requires short interval follow up after 6 months), 4 and 5 points corret t sponds to category IV (suspicious abnormality, biopsy should be considered) and 6, 7 and 8 points correspond to category V (highly suggestive of malignancy, biopsy mandatory) . The appropriate points for each lesion were thus given to each feature and were recorded in the evaluation score table (Table 1 ). The BItRADS category for the lesion was then identified (Figures 1t  3) . Tissue sampling was performed for cases with BIt RADS categories III, VI and V.
For the sampled lesions, the BItRADS category was then compared with the tissue sampling result (by FNAC, core biopsy or lumpectomy/ mastectomy hist t topathology of the tumor). For nontsampled lesions, the BItRADS category was determined by clinical folt t low up and repetition of MRI, ultrasonography (US) and/or mammography imaging at 12 and 24 months of the initial MRI scan. We then evaluated the accuracy of BItRADS category using the Fischer scoring system for both benign and malignant lesions. initial peak signal intensity increase within the first 3 minutes after contrast material administration relative to the precontrast signal intensity. b Continued signal intensity increase=signal intensity increase of greater than 10% relative to the initial peak signal intensity at 3-8 minutes. c Plateau=deviation of the signal intensity at 3-8 minutes of (10%) relative to the initial peak signal intensity. d Washout=signal intensity decrease of greater than 10% relative to the initial peak signal intensity at 3-8 minutes. 
RESULTS
Fortytone patients with identified breast lesions on mammography and ultrasonography were scanned with MRI using the 3D dynamic MRI protocol during May 2005 to September 2006. The age range of patients was 25 to 64 years with a mean age of 44.5 years and a met t dian age of 44 years. The total number of lesions identified in the 41 pat t tients was 70. Seven of the 70 lesions were seen only on MRI and hence were not proven by tissue sampling since we had not yet started MRItguided breast biopsy at that time and these were excluded from our study. Of the 63 lesions included in the study, 55 lesions were proved by tissue sampling. Twentytfive of the lesions were maligt t nant and 30 were proven to be benign. Eight of the 63 lesions diagnosed by MRI as benign were not biopsied and were followedtup clinically and radiologically at 12 and 24 months after the initial MRI.
The histopathology of the 25 malignant lesions were well differentiated ductal carcinoma in situ in 5, poorly differentiated infiltrating ductal carcinomas in 8, wellt differentiated invasive ductal carcinoma in 6, welltdift t ferentiated infiltrating lobular carcinomas in 5, and one welltdifferentiated mucinous carcinoma. Of the total breast lesions studied, the diagnostic yield of MRI was accurate in detecting malignant lesions in 92% and of benign lesions in 70%. Using the final histopathological diagnosis of the lesions as the gold standard , the sensit t tivity, specificity, positive and negative predictive values of MRI in diagnosing malignant breast lesions were 96%, 67%, 71% and 95%, respectively.
Morphological features of 25 pathologically proven malignant lesions
The margins were described as indistinct in 14 (56%) (Figure 1 ) and well circumscribed in 11 (44%). The shape was described as spiculated in 9 (36%) (Figure 1 ), round in 8 (32%) branching in 7 (28%) and lobular in 1 (4%). The enhancement pattern was homogeneous in 9 (36%), heterogeneous in 7 (28%) (Figure 1 ), peripht t eral rim in 8 (32%) and septated in 1 (4%). The mean size of the 25 carcinomas was 1.6 cm (range, 0.6 to 2.7 cm) for the homogeneously enhancing masses, 2.7 cm (range, 1.0 to 4.4 cm) for the heterogeneously enhancing masses, and 2.7 cm (range, 1.1 to 4.3 cm) for the rimtent t hancing masses. Carcinomas less than or equal to 1 cm were significantly more common in the homogeneously enhancing group than in the heterogeneously or rim ent t hancing groups. Of the 25 carcinomas, 10 (40%) were less than 1 cm.
Morphological features of 30 pathologically proven benign lesions
The margins were described as well circumscribed in 25 (83%) (Figure 2 ) and indistinct in 5 (17%) masses. The shape was described as round in 14 (47%), branching in 8 (27%), linear in 4 (13%) and spiculated in 1 (3%). The enhancement pattern was homogeneous in 16 (Figure 2 ). The bet t nign lesions that showed irregular or spiculated margin, branching and heterogeneous enhancement were proven to be chronic inflammation (Figure 3 ). The mean size was 2.2 cm (range, 0.5 to 4.0 cm) for the homogeneously enhancing masses, 3.2 cm (range, 0.3 to 6.0 cm) for the heterogeneously enhancing masses and 1.8 cm for the septated masses (range, 1.2 to 2.4 cm).
BI-RADS category of both benign and malignant le--sions
The were not sampled since we did not started MRt guided breast biopsy at the time of the study. For the bet t nign BItRADS categories (I and II), the impression on MR mammography was consistent with the final diagnot t sis of a benign lesions in 100% of the cases. For the mat t lignant MRM BItRADS category (V), this was found to be consistent with the final diagnosis of malignancy in 84% of the lesions and of MRM BItRADS category (IV) in 54% of the lesions. Thirty percent (9 out of 30) of benign lesions were diagnosed as malignant or probably malignant. No benign lesion was said to be of a category above II although in one case diagnosed morphologically as fibroadenoma and having BIRADS category III, the final diagnosis was invasive ductal carcinoma. The MRM BItRADS category was consistent with the histological diagnosis of the 25 malignant lesions in 92% and of the 30 benign lesions in 70% of the masses. The overlapping features of chronic inflammatory lesions with carcinomas (Table 2, Figure 3 ) was the reason that the MRM BIt RADS category was of lower accuracy in diagnosing the benign lesions as compared to the malignant lesions.
DISCUSSION
In our study, we found that the Fischer scoring system 1 and the BItRADS categories worked well for findings seen on MR imaging. For the 25 malignant lesions, only 2 masses were described as probably benign (BItRADS category III). Of these one mass showed homogeneous enhancement and the other mass showed heterogeneous enhancement. Both showed circumscribed margins; one was round and the other was lobular in shape. The sizes of both masses were small (10 mm and 20 mm). All the descriptors used in these 2 cases are associated with a benign finding (category II) or probably benign finding (category III) in the final assessment categories. The reat t son behind this could be due to multiple factors, includt t ing limited spatial resolution of the dynamic sequences used and the overlap of enhancement, both in terms of kinetic measurements and morphologic appearances of benign and malignant lesions, which precluded comt t plete differentiation of lesions. 8t11 If these small masses had not been biopsied, a 6tmonth followtup would have been performed. As with mammography, if a change were noted at that time, biopsy was performed.
It is becoming increasingly clear that while most int t vestigators have used either enhancement kinetics or let t sion morphology in an attempt to differentiate benign enhancing lesions from enhancing breast cancer, an integrated interpretation strategy where enhancement kinetics data and morphologic feature analysis are used together for image interpretation may be superior to the use of either method alone.
12 Further, since reader varit t ability remains a concern, an imaging lexicon similar to the BItRADS lexicon used in conventional xtrays mamt t mography, in which the architectural features are defined and illustrated, is needed.
To characterize a lesion as benign or malignant, one should integrate the morphological and the dynamic feat t tures of a lesion. The way to do it varies according to the experience of the investigator. For experienced radiolot t gists, the classification of lesions can be done without the need of the scoring system suggested by Fischer et al. 1 In this case the classification of the lesion is done based on obvious features, e.g. BItRADS V will be given to a stellate shape or spiculated border irrespective of the ent t hancement kinetics 13, 14 and for other lesions with irregut t lar shape and nontsmooth borders and heterogeneous architecture the kinetics are referred to; if there is strong enhancement and washout it is classified as BItRADS V and if intermediate enhancement with plateau or pert t sistent time course it will then be classified as BItRADS IV. Classifying a lesion using this method works very well for experienced radiologists, but for inexperienced radiologists this might be confusing and might cause overt or underestimation of the BItRADS category of a lesion.
Evaluating the enhancement curves can be done with either a qualitative 11 or quantitative method. 1 Kuhl et al 8 described three types of timetintensity curves: type I (steady enhancement), where a persistent increase in signal intensity is present beyond 2 minutes after cont t trast agent injection; type II (plateau), where the maxit t mum signal intensity is achieved in the first 2 minutes and then remains fairly constant; and type III (washt t out), where the maximum signal intensity is achieved in the first 2 minutes and then decreases over time. It has been reported that the type I curve is usually seen in benign lesions and normal breast parenchyma, the type III curve is mostly seen in malignant lesions and some fibroadenomas and the type II curve is equivocal and seen in some benign lesions and many malignant let t sions. 8 The qualitative method needs experience and is prone to under or overestimating the curve pattern espet t cially in deciding whether it is a plateau (type II curve) or a washtout (type III curve) pattern. The quantitative method, however, is easier and gives the inexperienced reader more confidence in characterizing the enhancet t ment curve of a lesion.
Nontenhancing internal septations, a descriptor usut t ally associated with fibroadenomas, is a sign that is no longer exclusive to benign lesions since recent results of a study by Schnall et al 11 revealed that 47% of maligt t nant lesions were shown to have nonenhancing internal septa. In our study, one septated mass that was detected and given BItRADS III category proved to be well dift t ferentiated invasive ductal carcinoma. None of the 25 carcinomas was assigned a final assessment of category I or II. Also, most of them were assigned a BItRADS category IV (28%) or category V (64%), necessitating biopsy even by those radiologists who had no experience interpreting breast MR images.
For the 30 benign lesions the overall accuracy was less (70%). Three lesions were scored as BItRADS V and 6 lesions as BItRADS IV. Looking at the pathot t logical diagnosis, morphology and the kinetics of these lesions (Table 2) , we found that 5 of these lesions were chronic inflammatory lesions and 1 mass was scar tist t sue. The morphologic features of these inflammatory lesions were overlapping with those of the malignant let t sions (Figure 3 ). The difficulty in accurately differentiatt t ing chronic inflammation from invasive carcinoma was also reported by Rieber et al. 15 The inclusion of chronic inflammatory lesions in our study is the main reason for a reduced accuracy since MRI is not a good tool for the differentiation of benign from malignancy in such a clinical situation.
In our study, we noticed a higher prevalence of hot t mogenous enhancement than heterogeneous and rim enhancement in malignant lesions. We also noticed that the mean size of carcinomas showing homogeneous ent t hancement was smaller than the mean size of carcinot t mas showing rim or heterogeneous enhancement. The reason behind this could be that 40% of the carcinomas in the current series were less than 1 cm in size. Rim enhancement, seen in 33% of the ductal carcinomas and in 60% of the lobular carcinomas in this series, is cont t sidered a suspicious morphologic feature. 2 The case of mucinous carcinoma in this series did not exhibit rim enhancement.
Nunes et al 5 found that none of the malignant masses had smooth borders, unlike our study in which 44% of the carcinomas had circumscribed borders. Nevertheless, most of these lesions had other more worrisome descriptors, such as heterogeneous or rim enhancement, which could be interpreted as malignancy as previously reported. 13 Moreover, mammographically circumscribed masses can be malignant, particularly the specific histologic subtypes of medullary, colloid, and papillary carcinoma as 5% to 6% of malignant masses have been described as circumscribed. 16 In our study, we noted that there was a good cort t relation between the MRMtBItRADS final assessment category and the eventual diagnosis obtained on histot t pathology or followtup. One weakness of our study was that we were forced to exclude 7 lesions from the study and analysis as they required MRtguided biopsy that we did not perform at the start of the study. It is no doubt important to have the facility of performing bit t opsies under MR guidance for lesions not accessible by other modalities and in whom a wait and watch policy is not advised.
It is logical that mammographers who are accust t tomed to evaluating breast lesions using BItRADS terms on mammography can readily translate those skills to MRI. The assignment of a final assessment category, as in mammography, indicates to the refert t ring physician what appropriate step should be taken next and what information should be included in the report.
In conclusion, the MRM BItRADS lexicon using the Fischer system is easy to apply and very useful and accurate in characterizing breast lesions. Overlapping MR features between some benign lesions like chronic inflammation and malignancy that might reduce the specificity need to be interpreted in conjunction with the clinical presentation and all other pertinent breast imaging studies, such as mammography and ultrasot t nography.
